Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Histone Modifications as Biomarkers for Immunotherapy.

Taylor EM, Koss B, Davis LE, Tackett AJ.

Methods Mol Biol. 2020;2055:213-228. doi: 10.1007/978-1-4939-9773-2_10.

PMID:
31502154
2.

PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation.

Ren Z, Ahn JH, Liu H, Tsai YH, Bhanu NV, Koss B, Allison DF, Ma A, Storey AJ, Wang P, Mackintosh SG, Edmondson RD, Groen RWJ, Martens AC, Garcia BA, Tackett AJ, Jin J, Cai L, Zheng D, Wang GG.

Blood. 2019 Oct 3;134(14):1176-1189. doi: 10.1182/blood.2019000578. Epub 2019 Aug 5.

PMID:
31383640
3.

Effect of Sulforaphane and 5-Aza-2'-Deoxycytidine on Melanoma Cell Growth.

Chiang TC, Koss B, Su LJ, Washam CL, Byrum SD, Storey A, Tackett AJ.

Medicines (Basel). 2019 Jun 27;6(3). pii: E71. doi: 10.3390/medicines6030071.

4.

Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.

Lee T, Christov PP, Shaw S, Tarr JC, Zhao B, Veerasamy N, Jeon KO, Mills JJ, Bian Z, Sensintaffar JL, Arnold AL, Fogarty SA, Perry E, Ramsey HE, Cook RS, Hollingshead M, Davis Millin M, Lee KM, Koss B, Budhraja A, Opferman JT, Kim K, Arteaga CL, Moore WJ, Olejniczak ET, Savona MR, Fesik SW.

J Med Chem. 2019 Apr 25;62(8):3971-3988. doi: 10.1021/acs.jmedchem.8b01991. Epub 2019 Apr 16.

PMID:
30929420
5.

Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma.

Shields BD, Koss B, Taylor EM, Storey AJ, West KL, Byrum SD, Mackintosh SG, Edmondson R, Mahmoud F, Shalin SC, Tackett AJ.

Cancer Res. 2019 Mar 15;79(6):1113-1123. doi: 10.1158/0008-5472.CAN-18-1722. Epub 2019 Jan 23.

PMID:
30674537
6.

Indicators of responsiveness to immune checkpoint inhibitors.

Shields BD, Mahmoud F, Taylor EM, Byrum SD, Sengupta D, Koss B, Baldini G, Ransom S, Cline K, Mackintosh SG, Edmondson RD, Shalin S, Tackett AJ.

Sci Rep. 2017 Apr 11;7(1):807. doi: 10.1038/s41598-017-01000-2.

7.

Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.

Lee T, Bian Z, Zhao B, Hogdal LJ, Sensintaffar JL, Goodwin CM, Belmar J, Shaw S, Tarr JC, Veerasamy N, Matulis SM, Koss B, Fischer MA, Arnold AL, Camper DV, Browning CF, Rossanese OW, Budhraja A, Opferman J, Boise LH, Savona MR, Letai A, Olejniczak ET, Fesik SW.

FEBS Lett. 2017 Jan;591(1):240-251. doi: 10.1002/1873-3468.12497. Epub 2016 Dec 19.

8.

Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines.

Koss B, Ryan J, Budhraja A, Szarama K, Yang X, Bathina M, Cardone MH, Nikolovska-Coleska Z, Letai A, Opferman JT.

Oncotarget. 2016 Mar 8;7(10):11500-11. doi: 10.18632/oncotarget.7204.

9.

Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways.

Haverkamp JM, Smith AM, Weinlich R, Dillon CP, Qualls JE, Neale G, Koss B, Kim Y, Bronte V, Herold MJ, Green DR, Opferman JT, Murray PJ.

Immunity. 2014 Dec 18;41(6):947-59. doi: 10.1016/j.immuni.2014.10.020. Epub 2014 Dec 11.

10.

Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia.

Koss B, Morrison J, Perciavalle RM, Singh H, Rehg JE, Williams RT, Opferman JT.

Blood. 2013 Aug 29;122(9):1587-98. doi: 10.1182/blood-2012-06-440230. Epub 2013 Jul 23.

11.

Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction.

Wang X, Bathina M, Lynch J, Koss B, Calabrese C, Frase S, Schuetz JD, Rehg JE, Opferman JT.

Genes Dev. 2013 Jun 15;27(12):1351-64. doi: 10.1101/gad.215855.113.

12.

Mcl-1 antagonizes Bax/Bak to promote effector CD4(+) and CD8(+) T-cell responses.

Tripathi P, Koss B, Opferman JT, Hildeman DA.

Cell Death Differ. 2013 Aug;20(8):998-1007. doi: 10.1038/cdd.2013.25. Epub 2013 Apr 5.

13.

A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival.

Cohen NA, Stewart ML, Gavathiotis E, Tepper JL, Bruekner SR, Koss B, Opferman JT, Walensky LD.

Chem Biol. 2012 Sep 21;19(9):1175-86. doi: 10.1016/j.chembiol.2012.07.018.

14.

Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration.

Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, Temirov J, Cleland MM, Pelletier S, Schuetz JD, Youle RJ, Green DR, Opferman JT.

Nat Cell Biol. 2012 Apr 29;14(6):575-83. doi: 10.1038/ncb2488.

15.

Ubiquitin-independent degradation of antiapoptotic MCL-1.

Stewart DP, Koss B, Bathina M, Perciavalle RM, Bisanz K, Opferman JT.

Mol Cell Biol. 2010 Jun;30(12):3099-110. doi: 10.1128/MCB.01266-09. Epub 2010 Apr 12.

16.

A novel wearable apnea dive computer for continuous plethysmographic monitoring of oxygen saturation and heart rate.

Kuch B, Koss B, Dujic Z, Buttazzo G, Sieber A.

Diving Hyperb Med. 2010 Mar;40(1):34-40.

PMID:
23111837
17.
18.

Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose.

Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, Ober BA, Huesman RH, Derenzo SE.

J Comput Assist Tomogr. 1983 Aug;7(4):590-8.

PMID:
6602819
19.

Central auditory processing. IV. Ear dominance--spatial and temporal complexity.

Efron R, Koss B, Yund EW.

Brain Lang. 1983 Jul;19(2):264-82.

PMID:
6883073
20.

Central auditory processing. III. The "cocktail party" effect and anterior temporal lobectomy.

Efron R, Crandall PH, Koss B, Divenyi PL, Yund EW.

Brain Lang. 1983 Jul;19(2):254-63.

PMID:
6883072
21.

Saccadic intrusions in Alzheimer-type dementia.

Jones A, Friedland RP, Koss B, Stark L, Thompkins-Ober BA.

J Neurol. 1983;229(3):189-94.

PMID:
6191010
23.

Relationship of neuronal activity to gross movement-related potentials in monkey pre- and postcentral cortex.

Arezzo J, Vaughan HG Jr, Koss B.

Brain Res. 1977 Aug 26;132(2):362-9. No abstract available.

PMID:
407977

Supplemental Content

Support Center